Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13967148 | 0.93 | — | — | |
| SCHEMBL757001 | 0.89 | — | — | |
| SCHEMBL3991598 | 0.83 | CYP2C19 (0.34) | ALDH1A1SMN1; SMN2TSHRMAPK1MAPT | |
| SCHEMBL18120838 | 0.81 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2TSHRMAPK1MAPT | |
| SCHEMBL14347615 | 0.81 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRMAPK1MAPT | |
| SCHEMBL12632043 | 0.81 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRMAPK1MAPT | |
| SCHEMBL12632052 | 0.81 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRMAPK1MAPT | |
| SCHEMBL12594008 | 0.80 | CYP1A2 (0.35) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL18120837 | 0.78 | KDM4E (0.39) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12250751 | 0.78 | ALDH1A1 (0.30) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626144-B2 | Peptide derivatives and uses thereof | NOSOPHARM (FR) | 2020-04-21 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626144-B2 | Peptide derivatives and uses thereof | VIP, IAPP, NGLY1 | ALDH1A1 4866/4885SMN1; SMN2 2211/4885TSHR 759/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | ALDH1A1 4866/4885SMN1; SMN2 2211/4885TSHR 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.